How to deal with the impact of key monitoring drugs in 2020

[pharmaceutical network industry trends] a few days ago, Yuheng pharmaceutical released the 2019 performance forecast It is estimated that the annual net profit attributable to shareholders of listed companies is 2.4 billion yuan to 2.6 billion yuan, so it was questioned by Shenzhen Stock Exchange Recently, Yuheng pharmaceutical replied to the inquiry letter of Shenzhen Stock Exchange According to the explanation, the sales volume of the main products of Shanghai Huatuo and Nanjing Wanchuan, such as sodium creatine phosphate for injection and brain protein hydrolysate for injection of Pude pharmaceutical products, were listed in the key monitoring catalogue, which significantly affected by the key monitoring catalogue and the new version of the medical insurance catalogue It is understood that in July 2019, the national health and Health Commission issued the notice on printing and distributing the first batch of national key monitoring and rational drug use catalogue (chemical and biological products), requiring all medical institutions to focus on monitoring the clinical application of drugs in the catalogue, and strengthening the clinical use monitoring and performance evaluation of drugs Among them, sodium creatine phosphate and cerebroprotein hydrolysate are listed The key monitoring of drug catalogue is an important safeguard measure to strengthen the management of clinical application of auxiliary drugs in medical institutions, standardize the clinical application of auxiliary drugs, improve the level of rational use of drugs, and safeguard the health rights and interests of the people In fact, since 2015, the state has issued a series of policies to promote the introduction and implementation of the catalogue of rational drugs At present, it seems that it has a great impact on related drugs According to insiders, one of its companies has a variety in its catalogue, and its sales have dropped by 50% In fact, among many affected pharmaceutical enterprises, Yuheng pharmaceutical industry is not one that has been greatly affected Beijing Sihuan Pharmaceutical Co., Ltd has 7 products affected, including: ganglioside, troxerutin cerebroprotein hydrolysate, cerebrosine and carnosine, cinepazide maleate Previously, the industry had estimated that the affected market size might exceed 7 billion yuan   In addition, in the notice of the leading group of deepening the reform of the medical and health system on further promoting the experience of deepening the reform of the medical and health system in Fujian Province and Sanming City issued by the state earlier, it was clear that by the end of December 2019, all provinces should formulate and issue the provincial catalogue of key drugs for monitoring the rational use of drugs (chemical drugs and biological products), and establish the key drug monitoring by the end of December 2020 Mechanism It can be seen from this that in 2020, the list of key monitored drugs will blossom all over the country, further strengthen the management and standardization of drug use list in medical institutions, promote all kinds of medical institutions at all levels to adjust and optimize drug use list in time, and promote rational drug use Therefore, for pharmaceutical companies, relevant enterprises should adjust their strategic layout and optimize product lines ahead of schedule In addition, we should carry out marketing model reform and strengthen the development of private hospitals and terminals In the future, under the policy combination of dynamic adjustment of key monitoring catalogue and other drug supervision, the situation of key monitoring drugs will only become more and more difficult In this case, we should pay attention to the rationality of hospital medication, professional promotion is the king.